These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19398818)

  • 21. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
    Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating obsessive compulsive disorder.
    Veale D
    Practitioner; 2002 Mar; 246(1632):181, 184-6. PubMed ID: 11901781
    [No Abstract]   [Full Text] [Related]  

  • 24. The assessment of drugs in obsessional states.
    Philpott R
    Br J Clin Pharmacol; 1976 Feb; 3(1 Suppl 1):91-5. PubMed ID: 973952
    [No Abstract]   [Full Text] [Related]  

  • 25. Obsessive-compulsive disorder in elderly patients.
    Jackson CW
    Drugs Aging; 1995 Dec; 7(6):438-48. PubMed ID: 8601051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of clomipramine in obsessive-compulsive disorder.
    Howland RH
    Anxiety; 1996; 2(1):56-7. PubMed ID: 9160602
    [No Abstract]   [Full Text] [Related]  

  • 27. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study.
    Flament MF; Rapoport JL; Berg CJ; Sceery W; Kilts C; Mellström B; Linnoila M
    Arch Gen Psychiatry; 1985 Oct; 42(10):977-83. PubMed ID: 3899048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adults with early-onset obsessive-compulsive disorder.
    Rosario-Campos MC; Leckman JF; Mercadante MT; Shavitt RG; Prado HS; Sada P; Zamignani D; Miguel EC
    Am J Psychiatry; 2001 Nov; 158(11):1899-903. PubMed ID: 11691698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
    O'Sullivan G; Noshirvani H; Marks I; Monteiro W; Lelliott P
    J Clin Psychiatry; 1991 Apr; 52(4):150-5. PubMed ID: 2016246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and treatment of obsessive-compulsive disorder and related disorders.
    Dell'Osso B; Altamura AC; Mundo E; Marazziti D; Hollander E
    Int J Clin Pract; 2007 Jan; 61(1):98-104. PubMed ID: 17229184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evidence-based pharmacotherapy and other somatic treatment approaches for obsessive-compulsive disorder: state of the art].
    Kordon A; Zurowski B; Wahl K; Hohagen F
    Nervenarzt; 2011 Mar; 82(3):319-20, 322-4. PubMed ID: 21340636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment.
    Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C
    Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obsessive-compulsive disorder: unearthing a hidden problem.
    El-Sayegh S; Bea S; Agelopoulos A
    Cleve Clin J Med; 2003 Oct; 70(10):824-5, 829-30, 832-3, passim. PubMed ID: 14621230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia.
    Marazziti D; Carlini M; Dell'Osso L
    Curr Top Med Chem; 2012; 12(4):238-53. PubMed ID: 22204483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response versus remission in obsessive-compulsive disorder.
    Simpson HB; Huppert JD; Petkova E; Foa EB; Liebowitz MR
    J Clin Psychiatry; 2006 Feb; 67(2):269-76. PubMed ID: 16566623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obsessive compulsive disorder as a cause of atypical eating disorder: a case report.
    Garcia FD; Houy-Durand E; Thibaut F; Dechelotte P
    Eur Eat Disord Rev; 2009 Nov; 17(6):444-7. PubMed ID: 19851993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breakthrough in psychiatric care: pharmacological treatment of obsessive-compulsive disorders with implications for nursing care.
    Giger JN; Davidhizar R; Poole VL
    J Pract Nurs; 2002; 52(2):12-6; quiz 17, 21. PubMed ID: 12122747
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.